319 related articles for article (PubMed ID: 35616289)
1. Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
Alghamri MS; Banerjee K; Mujeeb AA; Mauser A; Taher A; Thalla R; McClellan BL; Varela ML; Stamatovic SM; Martinez-Revollar G; Andjelkovic AV; Gregory JV; Kadiyala P; Calinescu A; Jiménez JA; Apfelbaum AA; Lawlor ER; Carney S; Comba A; Faisal SM; Barissi M; Edwards MB; Appelman H; Sun Y; Gan J; Ackermann R; Schwendeman A; Candolfi M; Olin MR; Lahann J; Lowenstein PR; Castro MG
ACS Nano; 2022 Jun; 16(6):8729-8750. PubMed ID: 35616289
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.
Gatti M; Pattarozzi A; Bajetto A; Würth R; Daga A; Fiaschi P; Zona G; Florio T; Barbieri F
Toxicology; 2013 Dec; 314(2-3):209-20. PubMed ID: 24157575
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
5. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
6. Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling.
Goffart N; Kroonen J; Di Valentin E; Dedobbeleer M; Denne A; Martinive P; Rogister B
Neuro Oncol; 2015 Jan; 17(1):81-94. PubMed ID: 25085362
[TBL] [Abstract][Full Text] [Related]
7. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
9. CXCL12 mediates trophic interactions between endothelial and tumor cells in glioblastoma.
Rao S; Sengupta R; Choe EJ; Woerner BM; Jackson E; Sun T; Leonard J; Piwnica-Worms D; Rubin JB
PLoS One; 2012; 7(3):e33005. PubMed ID: 22427929
[TBL] [Abstract][Full Text] [Related]
10. CXCL12/CXCR4 promotes motility and proliferation of glioma cells.
do Carmo A; Patricio I; Cruz MT; Carvalheiro H; Oliveira CR; Lopes MC
Cancer Biol Ther; 2010 Jan; 9(1):56-65. PubMed ID: 19923906
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
12. CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma.
Hsieh HT; Huang HC; Chung CW; Chiang CC; Hsia T; Wu HF; Huang RL; Chiang CS; Wang J; Lu TT; Chen Y
J Control Release; 2022 Dec; 352():920-930. PubMed ID: 36334859
[TBL] [Abstract][Full Text] [Related]
13. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
Gravina GL; Mancini A; Colapietro A; Vitale F; Vetuschi A; Pompili S; Rossi G; Marampon F; Richardson PJ; Patient L; Patient L; Burbidge S; Festuccia C
Tumour Biol; 2017 Jun; 39(6):1010428317695528. PubMed ID: 28639900
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
15. High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.
Kadiyala P; Li D; Nuñez FM; Altshuler D; Doherty R; Kuai R; Yu M; Kamran N; Edwards M; Moon JJ; Lowenstein PR; Castro MG; Schwendeman A
ACS Nano; 2019 Feb; 13(2):1365-1384. PubMed ID: 30721028
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.
Yadav VN; Zamler D; Baker GJ; Kadiyala P; Erdreich-Epstein A; DeCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
Oncotarget; 2016 Dec; 7(50):83701-83719. PubMed ID: 27863376
[TBL] [Abstract][Full Text] [Related]
17. Survival and Proliferation of Neural Progenitor-Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism.
Calinescu AA; Yadav VN; Carballo E; Kadiyala P; Tran D; Zamler DB; Doherty R; Srikanth M; Lowenstein PR; Castro MG
Clin Cancer Res; 2017 Mar; 23(5):1250-1262. PubMed ID: 27542769
[No Abstract] [Full Text] [Related]
18. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4.
Yi L; Zhou X; Li T; Liu P; Hai L; Tong L; Ma H; Tao Z; Xie Y; Zhang C; Yu S; Yang X
J Exp Clin Cancer Res; 2019 Aug; 38(1):339. PubMed ID: 31382985
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Tabouret E; Tchoghandjian A; Denicolai E; Delfino C; Metellus P; Graillon T; Boucard C; Nanni I; Padovani L; Ouafik L; Figarella-Branger D; Chinot O
Oncotarget; 2015 May; 6(13):11664-75. PubMed ID: 25860928
[TBL] [Abstract][Full Text] [Related]
20. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
